Estela Rodriguez, Associate Director of Community Outreach in Thoracic Oncology at the University of Miami’s Sylvester Comprehensive Cancer Center, shared a post on X:
“Catching up with the ELCC26 excitement for new targeted therapies for KRAS G12D (5% of lung cancer)
Setidegrasib – first-in-class, PROTAC (Proteolysis Targeting Chimera) protein degrader that targets the KRAS G12D mutation in Advanced NSCLC and Pancreatic Cancer Phase 1 NEJM publication ,N=203.
Partial Response (PR):
- 36% in NSCLC
- 24% in Pancreatic Cancer
Adverse Events (AEs) ≥ 3: 42% (IRRs, nausea).
Title: Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
Authores: Wungki Park, Anup Kasi, Alexander I. Spira, Luis Paz-Ares Rodríguez, Benjamin O. Herzberg, Meredith S. Pelster, Anthony W. Tolcher, Yasutoshi Kuboki, Shigehisa Kitano, Hirokazu Shoji, Judy S. Wang, Jordan D. Berlin, Antoine Hollebecque, Patricia LoRusso, Christos Fountzilas, Philippe A. Cassier, Tomohiro Nishina, Daisuke Sakai, Chiaki Inagaki, Daniel Morgensztern, Makoto Ueno, Minkyu Jung, Sang-We Kim, Pasi A. Jänne, Antoine Italiano, Benoît You, T Macarulla, Hisaki Fujii, Aditya Shetty, Ying Lu, Daniel Cui, Shilpa Kadam, Stanley C. Gill, Junko Toyoshima, Takeshi Saito, and Jonathan W. Goldman.
Other articles featuring Estela Rodriguez on OncoDaily.